Literature DB >> 12235313

Optic neuromyelitis syndrome in Brazilian patients.

R M Papais-Alvarenga1, C M Miranda-Santos, M Puccioni-Sohler, A M V de Almeida, S Oliveira, C A Basilio De Oliveira, H Alvarenga, C M Poser.   

Abstract

OBJECTIVES: To report the clinical features and outcome of 24 Brazilian patients with optic neuromyelitis syndrome (ONM); discuss the underlying pathological events associated with the ONM syndrome; review the nosological situation of ONM in the group of inflammatory and demyelinating diseases of the central nervous system. PATIENTS AND METHODS: Patients with ONM treated at the Hospital da Lagoa, Rio de Janeiro were studied. Demographic, clinical, magnetic resonance imaging, cerebrospinal fluid, and pathological data were analysed.
RESULTS: The study consisted of 20 women, four men of whom 10 were white and 14 Afro-Brazilians. Clinical course was recurrent in 22 cases and monophasic in two. Neurological manifestations at inclusion were: sensory impairment (66%), bilateral (41.6%) or unilateral blindness (20.8%), paraplegia or quadriplegia (37.5%). The EDSS was moderate/severe in 70.8%. The underlying pathological events were respectively pulmonary tuberculosis and upper respiratory infection in the two monophasic cases; in the 22 recurrent ONM patients: pulmonary tuberculosis (3), neurocysticercosis (1), polyarteritis nodosa (1), antinuclear antibody and rheumatoid factor (1), antiphospholipid antibody primary syndrome (1), diabetes mellitus (1), hypothyroidism (1), and amenorrhea-galactorrhea (4). Normal cerebrospinal fluid was found in 52% and an inflammatory profile in 48%. Only four recurrent ONM white patients had brain and spinal cord magnetic resonance imaging and cerebrospinal fluid findings compatible with the diagnosis of multiple sclerosis. Large lesions were seen in 62% of spinal magnetic resonance images. Six of 12 recurrent ONM Afro-Brazilian died. There were no statistical differences in the demographic data of the two ethnic groups. Afro-Brazilians were significantly more severely impaired and had a higher mortality rate than the white patients.
CONCLUSION: These cases were classified as follows: two monophasic acute disseminated encephalomyelitis; one recurrent disseminated encephalomyelitis; three recurrent ONM associated with Hughes syndrome, autoantibodies and polyarteritis nodosa; six recurrent ONM with endocrinopathies; and finally, four multiple sclerosis cases. The remaining cases were not associated with any other condition. It would seem clear that ONM is a syndrome rather than a single disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12235313      PMCID: PMC1738088          DOI: 10.1136/jnnp.73.4.429

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  16 in total

1.  The clinical course of neuromyelitis optica (Devic's syndrome).

Authors:  D M Wingerchuk; W F Hogancamp; P C O'Brien; B G Weinshenker
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

2.  The pathogenesis of multiple sclerosis: a commentary.

Authors:  C M Poser
Journal:  Clin Neurol Neurosurg       Date:  2000-12       Impact factor: 1.876

3.  DQB1*0602 confers genetic susceptibility to multiple sclerosis in Afro-Brazilians.

Authors:  A Caballero; S Alvés-León; R Papais-Alvarenga; O Fernández; G Navarro; A Alonso
Journal:  Tissue Antigens       Date:  1999-11

4.  Multiple sclerosis in Brazil. Analysis of cerebrospinal fluid by standard methods.

Authors:  M Puccioni-Sohler; F Passeri; C Oliveira; C O Brandão; R Papaiz-Alvarenga
Journal:  Arq Neuropsiquiatr       Date:  1999-12       Impact factor: 1.420

Review 5.  The epidemiology of multiple sclerosis: a general overview.

Authors:  C M Poser
Journal:  Ann Neurol       Date:  1994-12       Impact factor: 10.422

Review 6.  Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature.

Authors:  M J Cuadrado; M A Khamashta; A Ballesteros; T Godfrey; M J Simon; G R Hughes
Journal:  Medicine (Baltimore)       Date:  2000-01       Impact factor: 1.889

7.  Recurrent optic neuromyelitis with endocrinopathies: a new syndrome.

Authors:  J C Vernant; P Cabre; D Smadja; H Merle; I Caubarrère; J Mikol; C M Poser
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910

Review 8.  Epidemiology of multiple sclerosis.

Authors:  B G Weinshenker
Journal:  Neurol Clin       Date:  1996-05       Impact factor: 3.806

9.  Devic's neuromyelitis optica: a clinicopathological study of 8 patients.

Authors:  R N Mandler; L E Davis; D R Jeffery; M Kornfeld
Journal:  Ann Neurol       Date:  1993-08       Impact factor: 10.422

10.  A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity?

Authors:  D Karussis; R R Leker; A Ashkenazi; O Abramsky
Journal:  Ann Neurol       Date:  1998-10       Impact factor: 10.422

View more
  23 in total

1.  An epidemiological study of neuromyelitis optica in Cuba.

Authors:  Jose A Cabrera-Gómez; John F Kurtzke; Alina González-Quevedo; R Lara-Rodríguez
Journal:  J Neurol       Date:  2009-02-09       Impact factor: 4.849

2.  Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase.

Authors:  P O Barros; T Cassano; J Hygino; T B Ferreira; N Centurião; T M Kasahara; R M Andrade; U C Linhares; A F B Andrade; C C F Vasconcelos; R Alvarenga; R Marignier; C A M Bento
Journal:  Clin Exp Immunol       Date:  2015-12-01       Impact factor: 4.330

3.  The clinical course of idiopathic acute transverse myelitis in patients from Rio de Janeiro.

Authors:  Marina Papais Alvarenga; Luiz Claudio Santos Thuler; Silvio Peçanha Neto; Claudia Cristina Ferreira Vasconcelos; Solange Gomes Camargo; Marcos Papais Alvarenga; Regina Maria Papais-Alvarenga
Journal:  J Neurol       Date:  2010-02-03       Impact factor: 4.849

4.  Characteristics of Devic's disease (neuromyelitis optica) in Mexico.

Authors:  John Flores Rivera; John F Kurtzke; Vanessa J Alatriste Booth; Teresa Corona V
Journal:  J Neurol       Date:  2008-02-19       Impact factor: 4.849

5.  Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica.

Authors:  Zhihua Ren; Yan Wang; Tao Duan; Jilpa Patel; Thomas Liggett; Eileah Loda; Sarang Brahma; Rajendra Goswami; Carrie Grouse; Richard Byrne; Dusan Stefoski; Adil Javed; Stephen D Miller; Roumen Balabanov
Journal:  J Immunol       Date:  2012-09-24       Impact factor: 5.422

6.  Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution.

Authors:  Elisa Bizzoco; Francesco Lolli; Anna Maria Repice; Bahia Hakiki; Mario Falcini; Alessandro Barilaro; Rosanna Taiuti; Gianfranco Siracusa; Maria Pia Amato; Tiziana Biagioli; Silvia Lori; Marco Moretti; Annalisa Vinattieri; Patrizia Nencini; Luca Massacesi; Sabrina Matà
Journal:  J Neurol       Date:  2009-05-28       Impact factor: 4.849

7.  The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients.

Authors:  Ulisses C Linhares; Patrícia B Schiavoni; Priscila O Barros; Taissa M Kasahara; Bruna Teixeira; Thais B Ferreira; Regina Alvarenga; Joana Hygino; Morgana M M Vieira; Vera Carolina B Bittencourt; Regis M Andrade; Arnaldo F Andrade; Cleonice A M Bento
Journal:  J Clin Immunol       Date:  2012-09-05       Impact factor: 8.317

Review 8.  [Neuromyelitis optica].

Authors:  S Jarius; B Wildemann
Journal:  Nervenarzt       Date:  2007-12       Impact factor: 1.214

9.  Neuromyelitis optica spectrum disorder and active tuberculosis.

Authors:  James Kerr Grieve; Scott Day; David Connell; Jonathan O'Riordan
Journal:  BMJ Case Rep       Date:  2020-01-02

10.  Brain abnormalities in neuromyelitis optica spectrum disorder.

Authors:  Woojun Kim; Su-Hyun Kim; So-Young Huh; Ho Jin Kim
Journal:  Mult Scler Int       Date:  2012-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.